Iovance Biotherapeutics Financials - Benzinga

SPY765.50+0.17%QQQ739.44+0.21%BTC/USD83,632.97+0.21%DIA513.56+0.13%GLD383.10+0.05%TLT78.39+0.20%

Iovance Biotherapeutics Inc

IOVANASDAQ

Trade with Public

Trade with Public

$14.45

3.4631.48%

At close: Sep 29, 5:00 PM EST

$14.43

-0.02-0.14%

After Hours: 7:26 PM EST

PRO

Why Is It Moving?™:Iovance Biotherapeutics shares are trading higher after the company raised ...

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Iovance Biotherapeutics Financials

Iovance Biotherapeutics (IOVA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Iovance Biotherapeutics’ Amtagvi Demand Drives 2026 Revenue Guidance Bump, Stock Soars

Iovance Biotherapeutics upgrades 2026 revenue guidance to $410 million-$420 million. Key technicals, analyst targets, and Amtagvi demand analyzed.

Vandana Singh

Crude Oil Down 1%; US Job Openings Fall In August

U.S. stocks fell as job openings declined; oil slid and gold rose. BKYI doubled, SSTI surged, while NIVF plunged 77% and QURE fell 37%.

Avi Kapoor

PRO
Iovance Raises FY2026 Total Revenue Guidance From $350M-$370M To $410M-$420M

Benzinga Newsdesk

Iovance (IOVA) Stock Soars After Better-Than-Expected Q2 Results

Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares are surging Thursday after the cancer therapy company shattered second-quarter expectations on both the top and bottom lines. Here's what you should know.

Evette Mitkov

PRO
Iovance Biotherapeutics Affirms FY2026 Sales Guidance of $350.000M-$370.000M vs $362.083M Est

Iovance Biotherapeutics (NASDAQ:IOVA) affirms FY2026 sales outlook from $350.000 million-$370.000 million to $350.000 million-$370.000 million vs $362.083 million estimate.

Benzinga Newsdesk

PRO
Iovance Biotherapeutics Q2 EPS $(0.11) Beats $(0.14) Estimate, Sales $99.313M Beat $87.832M Estimate

Benzinga Newsdesk